Cancer Therapy Tamoxifen May Hold Promise for 2 Batten Types

Cancer Therapy Tamoxifen May Hold Promise for 2 Batten Types

313265

Cancer Therapy Tamoxifen May Hold Promise for 2 Batten Types

A screening of U.S.-approved therapies revealed that tamoxifen, an oral cancer therapy, is able to effectively reduce the accumulation of a fatty molecule called globotriaosylceramide, or Gb3, in cellular models of two forms of Batten disease. It worked without compromising cell survival, a study showed. That study found that the levels of Gb3 are abnormally increased in cellular and mouse models of these two Batten types, specifically neuronal ceroid lipofuscinosis type 3 — known as CLN3…

You must be logged in to read/download the full post.